Regeneration Biomedical

Regeneration Biomedical is a private, pre-revenue biotech advancing a first-in-class, autologous stem cell therapy platform targeting major neurodegenerative diseases. Its core innovation is the intracranial delivery of Wnt-activated adipose-derived stem cells, aiming to modulate inflammation and promote regeneration within the brain. The company is led by a team with decades of medical and research experience and is currently recruiting for a Phase 1 trial in Alzheimer's disease, with a broad pipeline intended for ALS, Multiple Sclerosis, Parkinson's, stroke, and TBI. Its success hinges on demonstrating safety and efficacy in its ongoing clinical work and navigating the complex regulatory pathway for a novel biologic intervention.

Autologous, adipose-derived stem cells that are Wnt-activated and delivered via direct intracerebral injection to bypass the blood-brain barrier. Aims to reduce neuroinflammation and promote endogenous regeneration.

RBI competes in the crowded and challenging neurodegenerative disease space against large pharma and biotech firms pursuing antibody, gene therapy, and other cell-based approaches. Its key differentiator is the direct intracerebral delivery of Wnt-activated autologous cells, a niche but unproven strategy compared to more conventional systemic therapies.